Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMB-365 and TMB-380 as Maintenance Therapy in HIV-1 Infected Individuals
NCT07215468Phase 2Active, not recruiting
- Sponsor
- TaiMed Biologics
- Start
- Dec 2025
- Primary completion
- May 2027
- Modality
- Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
A Phase 2 trial of TMB-365, VRC07-523LS in human immunodeficiency virus infection (HIV), sponsored by TaiMed Biologics. Started Dec 2025; status: active, not recruiting.
02
Drugs
TMB-365VRC07-523LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07215468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215468.